HIND — Vyome Holdings Share News
0.000.00%
- $12.56m
- $5.94m
- $0.32m
Brief: Reshape Lifesciences Announces ASMBS And IFSO have issued updated guidelines on indications for metabolic and bariatric surgery, including the Lap-Band
Brief: ReShape Lifesciences Announces Publication Of Data On Proprietary Diabetes Bloc-Stim Neuromodulation System
Brief: Reshape Lifesciences Awarded Phase I NIH SBIR Grant To Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device
Brief: Reshape Lifesciences Appoints Seasoned Sales And Marketing Executive, Nick Ansari, As Senior Vice President Of Global Commercial Operations
Brief: ReShape Lifesciences Reports Q2 2022 Results
ReShape Lifesciences Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Reshape Lifesciences Receives FDA 510(K) Clearance For The Gibi HD Calibration Tubes For Use In Gastric And Bariatric Procedures
Brief: Reshape Lifesciences- On July 19,Received Written Notice From Nasdaq Indicating That Co Is Not In Compliance With $1.00 Minimum Bid Price Requirement
Brief: ReShape Lifesciences Enters Into Warrant Exercise Transaction For $2.5 Million In Gross Proceeds
Brief: ReShape Lifesciences And OpenLoop To Provide Nationwide Virtual Health Services For Weight Loss And Wellness
ReShape Lifesciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: ReShape Lifesciences Reports Q1 Financial Results And Provides Corporate Update
ReShape Lifesciences Inc expected to post a loss of 34 cents a share - Earnings Preview
ReShape Lifesciences Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ReShape Lifesciences Reports Year Ended 2021 Financial And Operating Results
ReShape Lifesciences Inc expected to post a loss of 17 cents a share - Earnings Preview
ReShape Lifesciences Inc expected to post a loss of 17 cents a share - Earnings Preview
ReShape Lifesciences shares fall as Q3 loss widens
ReShape Lifesciences Inc reports results for the quarter ended in September - Earnings Summary